Bruce E. Johnson

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

S. Gabriel, M. Meyerson, W. Sellers, 2004, Science.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Robert T. Jones, A. McKenna, K. Cibulskis, 2015, Cancer discovery.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

H. Groen, Bruce E. Johnson, J. Rigas, 2016, The Lancet. Oncology.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

H. Groen, Bruce E. Johnson, E. Smit, 2016, The Lancet. Oncology.

Characterizing the cancer genome in lung adenocarcinoma

Derek Y. Chiang, S. Gabriel, E. Lander, 2007, Nature.

The BATTLE trial: personalizing therapy for lung cancer.

Edward S. Kim, S. Lippman, F. Khuri, 2011, Cancer discovery.

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

Bruce D Cheson, David A Mankoff, Daniel C Sullivan, 2005, Clinical Cancer Research.

Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma

Mark A. Rubin, Barbara A. Weir, Matthew Meyerson, 2009, Journal of cellular and molecular medicine.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

V. Rusch, Bruce E. Johnson, I. Wistuba, 2019, Journal of Clinical Oncology.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

M. Kris, V. Rusch, Bruce E. Johnson, 2018 .

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Jeffrey W. Clark, Bruce E. Johnson, G. Shapiro, 2014, Journal of the National Cancer Institute.

T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas.

Ilan R. Kirsch, Bruce E. Johnson, P. Bunn, 1985, The New England journal of medicine.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.

R. Gray, Bruce E. Johnson, S. Dahlberg, 2008, Journal of Clinical Oncology.

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Bo Li, Aviv Regev, Mario L. Suvà, 2020, Nature Medicine.

Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays

Eric S. Lander, Thomas J. Hudson, David M. Tanenbaum, 2000, Nature Biotechnology.

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines

David C Christiani, Cheng Li, Luc Girard, 2004, Oncogene.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Robert E. Jones, Gordon J. Freeman, 2016, Nature Communications.

LKB1 modulates lung cancer differentiation and metastasis

D. Neil Hayes, David C. Christiani, Kwok-Kin Wong, 2007, Nature.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

A. Redig, P. Jänne, Bruce E. Johnson, 2016, JAMA oncology.

Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States

Colleen Bouzan, M. Weinstein, Bruce E. Johnson, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

Matthew Meyerson, M. Meyerson, P. Jänne, 2004, Cancer Research.

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Aviv Regev, Mario L. Suvà, Nikhil Wagle, 2019, Nature Medicine.

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

Taebo Sim, Takayuki Kosaka, Nathanael S. Gray, 2016, Clinical Cancer Research.

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

Tae Min Kim, Bruce E. Johnson, Fabrice Barlesi, 2016 .

Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study.

Stephen J. Swensen, Milton C. Weinstein, Chung Yin Kong, 2008, Radiology.

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

C. Mermel, P. Jänne, Bruce E. Johnson, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.

P. Jänne, Bruce E. Johnson, D. Sugarbaker, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

M. Ladanyi, A. Iafrate, M. Kris, 2015, Cancer.

Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines.

D. Ettinger, Bruce E. Johnson, B. Johnson, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

Bruce E. Johnson, J. Soria, V. Papadimitrakopoulou, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

M. Socinski, Bruce E. Johnson, R. Govindan, 2017, Lung cancer.

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

Bruce E. Johnson, T. Lynch, C. Langer, 2007, Cancer.

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

Bruce E. Johnson, V. Miller, F. Kabbinavar, 2010 .

Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

P. Jänne, Bruce E. Johnson, L. Sequist, 2012 .

Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer

S. Steinberg, Bruce E. Johnson, F. Kaye, 2002, American journal of clinical oncology.

Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer.

K. Emmons, P. Catalano, Bruce E. Johnson, 2012, Lung cancer.

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

Nicholas D. Camarda, S. Carter, A. Iafrate, 2020, Nature Genetics.

Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America

P. Jänne, B. Freidlin, Bruce E. Johnson, 2002, Cancer.

Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasion

A. Regev, D. Schadendorf, B. Cleary, 2020, bioRxiv.